A lack of entrepreneurial behaviour has often been highlighted as a contributor to the decline in the research and development (R&D) productivity of the pharmaceutical industry. Here, we present an assessment of entrepreneurship in the industry, based on interviews with 26 former and current leaders of R&D departments at major pharmaceutical and biotechnology companies. Factors are highlighted that could be important in promoting entrepreneurial behaviour, which might serve as a catalyst for revitalizing R&D productivity.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Journal of Translational Medicine Open Access 27 April 2016
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Goodman, M. Pharma industry performance metrics: 2007–2012E. Nature Rev. Drug Discov. 7, 795 (2008).
Pisano, G. P. Science Business: The Promise, the Reality, and the Future of Biotech (Harvard Business School Press, Boston, Massachusetts, USA, 2006).
Cuervo, A., Ribeiro, D. & Roig, S (eds) Entrepreneurship: Concepts, Theory and Perspective (Springer, Berlin, Germany, 2007).
Schramm, C. J. The Entrepreneurial Imperative: How America's Economic Miracle Will Reshape the World (and Change Your Life) (HarperCollins, 2006).
Pharmaceutical Research and Manufacturers of America. PhRMA Annual Membership Survey. PhRMA website [online], (2009).
IMS Health. Global Pharmaceutical Sales, 2001–2008. IMS Health website [online], (2009).
Munos, B. Lessons from 60 years of pharmaceutical innovation. Nature Rev. Drug Discov. 8, 959–968 (2009).
With special thanks to D. Kaiser, M. Tribbitt and T. Flores for their research and editorial assistance. We would also like to thank the following colleagues who participated in these interviews: B. Adelman, R. Armstrong, L. Babiss, J. Boger, A. Busch, P. Corr, M. Fishman, T. Glenn, C. Goodman, B. Kirschbaum, J. Leiden, G. Milne, P. Needleman, G. Neil, J. Patterson, S. Paul, J. Reinhardt, P. Ringrose, D. Rosen, L. Rosenberg, R. Ruffolo, V. Sato, B. Shapiro, A. Smith, G. Watanabe and T. Yamada (see Box 1).
The authors do not believe that any of them have competing financial interests as defined in the Nature journals' competing financial interest policy. However, in the interest of full disclosure, the authors state that Lesa Mitchell and Robert E. Litan are employees of the Ewing Marion Kauffman Foundation which is specifically engaged in research into and the proliferation of concepts relating to entrepreneurship generally. Frank L. Douglas is, among other pursuits, a Senior Fellow of the Ewing Marion Kauffman Foundation and V. K. Narayanan is, among other pursuits, an indirect recipient of grant monies given by the Foundation to Drexel University, Philadelphia, Pennsylvania, USA.
About this article
Cite this article
Douglas, F., Narayanan, V., Mitchell, L. et al. The case for entrepreneurship in R&D in the pharmaceutical industry. Nat Rev Drug Discov 9, 683–689 (2010). https://doi.org/10.1038/nrd3230
This article is cited by
Journal of Translational Medicine (2016)
Nature Reviews Drug Discovery (2014)
The Paradox of Scientific Excellence and the Search for Productivity in Pharmaceutical Research and Development
Clinical Pharmacology & Therapeutics (2014)
Nature Reviews Drug Discovery (2012)